The US Food and Drug Administration has hit Glenmark Pharmaceuticals Ltd., Mumbai, India, with a 3 October warning letter for a number of good manufacturing practice violations, including not addressing issues related to product grittiness in its topical creams and for not investigating temperature excursions.
The warning letter followed an inspection at the firm’s site in Baddi, India, following an inspection in April. The FDA...






